NSW Health advice

The Australian Technical Advisory Group on Immunisation (ATAGI) recently released advice about COVID-19 booster dose for specified groups as follows:

ATAGI advice recommends a 2023 COVID-19 vaccine booster dose for adults in the following groups, if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, and regardless of the number of prior doses received:

  • All adults aged 65 years and over
  • Adults aged 18-64 years who have medical comorbidities that increase their risk of severe COVID-19, or disability with significant or complex health needs.

ATAGI advises the following groups should consider a 2023 booster dose if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, and regardless of the number of prior doses received, based on an individual risk benefit assessment with their immunisation provider.

  • All adults aged 18-64 years without risk factors for severe COVID-19
  • Children and adolescents aged 5-17 years who have medical comorbidities that increase their risk of severe COVID-19, or disability with significant or complex health needs.

On this page

  1. COVID-19 vaccination clinics
  2. Authorities and licences
  3. COMIRNATY (Pfizer)
  4. Spikevax (Moderna)
  5. Nuvaxoid (Novavax)
  6. Contraindication form
  7. Adverse events
  8. Training resources
  9. More information

COVID-19 vaccination clinics

Authorities and licences

SPIKEVAX (Moderna)

Nuvaxovid (Novavax) vaccine

Adverse events

Serious adverse events following immunisation (AEFI) are notifiable conditions in NSW. Healthcare providers are required to report any serious AEFI to NSW Health and the Therapeutic Goods Administration. More information is available on Adverse events following immunisation (AEFI).

Training resources

Training modules are available for clinical staff including:

More information

Current as at: Wednesday 3 May 2023
Contact page owner: Health Protection NSW